FDA感染性疾病办公室抗菌药物耐药监管科学研究活动及FY2027资助机会
Office of Infectious Diseases Research Activities
FDA感染性疾病办公室围绕抗菌药物耐药开展监管科学研究,重点促进新型抗菌药物开发并推进临床试验设计科学。FY2027通过FDA广泛机构公告征集抗菌及抗真菌药物开发与耐药相关研究提案,并设淋病奈瑟菌耐药分子监测优先领域,BAA说明会于2026年12月8日举行,提案截止2027年1月22日。
Antimicrobial Regulatory Science Research
Antimicrobial drug resistance is a major threat to public health. In March 2015, The National Action Plan for Combating Antibiotic-resistant Bacteria was developed in response to Executive Order 13676: Combating Antibiotic-Resistant Bacteria, which was issued on September 18, 2014. The updated National Action Plan for 2020 -2025 continues to outline steps for implementing the National Strategy for Combating Antibiotic-Resistant Bacteria to address urgent and serious drug-resistant threats (bacteria and fungi) that affect people in the U.S. and around the world. The updated Plan follows the framework of CDC’s 2019 AR Threats Report and uses the term “antibiotic” to describe antibacterial and antifungal drugs, which kill bacteria and fungi, respectively. Implementation of the National Action Plan will also support World Health Assembly resolution 67.25 (Antimicrobial Resistance), which urges countries to take urgent action at the national, regional, and local levels to combat resistance.
The FDA’s roles in combatting antimicrobial drug resistance include:
- Facilitating the development of new antimicrobial drugs to treat patients; and
- Advancing the science of clinical trial design. The design and conduct of clinical trials to evaluate new antimicrobial drugs in patients with serious bacterial and fungal infections is challenging and therefore of particular interest for FDA’s regulatory science program.
Background
FY27 Funding Opportunities
The FDA funds research proposals through FDA’s Broad Agency Announcement for the Advanced Research and Development of Regulatory Science. This is a competitive announcement where research proposals to facilitate antibacterial and antifungal drug development and address antibacterial and antifungal drug resistance are evaluated.
- Research Priority Area for Molecular Surveillance of Antimicrobial Resistance in Neisseria gonorrhoeae (PDF - 202 KB)
Attend the Fiscal Year (FY) 2027 FDA Broad Agency Announcement Day on December 8, 2026, to learn more about the BAA submission process as well as the research priority area identified above.
Submissions are due by January 22, 2027, 5 pm ET
ORISE Fellowship Opportunities
- None currently available
Public Meetings
- Public Meetings (Upcoming and Past)
- Advancing Animal Models for Antibacterial Drug Development | March 5, 2020
- Current State and Further Development of Animal Models of Serious Infections Caused by Acinetobacter baumannii and Pseudomonas aeruginosa | March 1, 2017
Related Resources
来源:FDA 官方药品与生物制品信息 · fda.gov